NR3C2 and chronic kidney disease: A randomized controlled trial involving patients with stage 3b chronic kidney disease from primary care reported that in contrast to reported cardiorenal protective effects of nonsteroidal mineralocorticoid receptor antagonists (MRA), the steroidal MRA spironolactone did not reduce mortality or cardiovascular disease hospitalization compared to usual care.